Andrew Eugene Hendifar

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nat Med. 2026 Oct 23. George B, Singh H, Devoe CE, Chung V, Hosein PJ, Hendifar A, Kim DW, Valerin JB, Bekaii-Saab T, Cardin DB, Hidalgo M, Kasi PM, Leal AD, Pelster M, Fei N, Weekes CD, O'Hara MH, George TJ, Kazmi SM, Mizrahi JD, Nair S, Maiers M, Kheoh T, Amato G, Xavier J, Snyder JP, Milaszewski MH, Cabana-Puig X, Perry JR, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, Wainberg ZA, O'Reilly EM. PMID: 42919966.
      View in: PubMed   Mentions:
    2. Treatment-Stratified Immune-Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy. Diagnostics (Basel). 2026 Oct 13; 16(20). Kim A, Alsudaney M, Khattab O, Legaspi D, Kim N, Imran S, Alderete AE, Chen PJ, Jamil F, Liu J, Lim J, Koltsova E, Ayoub W, Hendifar A, Yang JD. PMID: 42938169; PMCID: PMC13703371.
      View in: PubMed   Mentions:
    3. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Psychooncology. 2026 Sep; 35(9):e70601. Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong J, Osipov A, Hendifar AE. PMID: 42714969; PMCID: PMC13557214.
      View in: PubMed   Mentions:
    4. Primary Resection and Metastasectomy for Well-Differentiated Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors: A National Cancer Database Analysis. Ann Surg Oncol. 2026 Aug 31. Sutton TL, Ventin M, Dumitra T, Arya S, Schwieger L, Ferrone CR, Hendifar AE, Gangi A. PMID: 42675351.
      View in: PubMed   Mentions:
    5. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nat Cancer. 2026 Sep; 7(9):1406-1418. Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S, Furuya H, Osipov A, Lorber J, Billet S, Morris A, Ten Hoeve-Scott J, Graeber T, Pandol SJ, Hendifar A, Bhowmick NA. PMID: 42675216; PMCID: PMC13600916.
      View in: PubMed   Mentions:
    6. Next-Generation Sequencing of Multivergent Morphologies in Colorectal Carcinomas Identifies Unique Targetable Alterations. Am J Surg Pathol. 2026 10 01; 50(10):1195-1204. Larson BK, Makhoul E, Gangi A, Gong J, Guindi M, Hendifar A, Hutchings D, Kozak M, Lai K, Osipov A, Vail E, Waters KM. PMID: 42494233.
      View in: PubMed   Mentions:    Fields:    
    7. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond. J Nucl Med. 2026 Jul 01; 67(7):1037-1040. Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. PMID: 42061947; PMCID: PMC13321983.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 Jul 23; 395(4):325-337. O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM, RASolute 302 Trial Investigators. PMID: 42223072.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    9. Pathogenic germline variants identified in pNEN patients during genetic testing. Endocr Oncol. 2026 Jan; 6(1):e250088. Arouchian T, Gangi A, Fung KW, Dumitra T, Levi A, Osipov A, Hendifar AE. PMID: 42245232; PMCID: PMC13232594.
      View in: PubMed   Mentions:
    10. Surgical and Oncologic Outcomes After Pancreatectomy for Pancreatic Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 and von Hippel-Lindau Syndrome: A Large, Multi-Institutional, Cohort Study. J Am Coll Surg. 2026 Jun 01; 242(6):1602-1612. Zhang L, Ventin M, Arya S, Gangi A, Hendifar AE, Nissen NN, Wei AC, Zureikat AH, He J, Ferrone CR, PAncreatic Neuroendocrine Disease Alliance (PANDA). PMID: 41642264.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening. Cancer Epidemiol Biomarkers Prev. 2026 Apr 01; 35(4):491-493. Vega MI, Billet S, Pigazzi A, Gangi A, Hendifar AE, Osipov A, Zaghiyan K, Nasseri Y, Murrell Z, Waters KM, Mehta P, Atkins KM, Felix GE, Hitchins MP, Gong J. PMID: 41918361.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630. Cancers (Basel). 2026 Feb 28; 18(5). Chang PJ, Hendifar AE, Gresham G, Ngo-Huang A, Oberstein PE, Parker N, Coveler AL, Precision Promise Consortium. PMID: 41827820; PMCID: PMC12984872.
      View in: PubMed   Mentions:
    13. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. J Clin Oncol. 2026 Sep 10; 44(26):2496-2506. Hendifar AE, Krishna V, Krishna V, Zhang H, Tarsode A, Nimgaonkar V, Smith K, Abdilleh K, Sonawane S, Neema A, Tiu E, Larson BK, Kazarov V, Moshayedi N, Hutchinson S, Bevacqua D, Doss S, Alvarez A, Watson D, Abuzeid WM, Grünwald BT, Noel M, Samdani R, Keith D, Sears RC, Sohal D, Fountzilas C, O'Kane GM, Grant RC, Osipov A, Collisson EA, Kiedrowski LA, Royce TJ, Joshi AR, Singhi AD, Knox JJ. PMID: 41671529; PMCID: PMC13557474.
      View in: PubMed   Mentions:    Fields:    
    14. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. Cancers (Basel). 2026 Feb 03; 18(3). Chiorean EG, Damle SR, Zhen DB, Whittle M, George B, Hochster H, Coveler AL, Hendifar A, Dragovich T, Safyan RA, King GT, Harris WP, Dion B, Stoll D'Astice A, Lee A, Thorsen S, Kugel S, Rosenthal A, Hingorani S. PMID: 41681979; PMCID: PMC12896646.
      View in: PubMed   Mentions:
    15. Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors. JAMA Surg. 2026 02 01; 161(2):142-151. Ventin M, Arya S, Zhang L, Gangi A, Fernandez Del-Castillo C, Qadan M, Hendifar AE, Cattaneo G, Liguori L, Osipov A, Sabbatino F, Nissen NN, Kosari K, Lillemoe KD, Wei AC, He J, Zureikat AH, Ferrone CR. PMID: 41405980; PMCID: PMC12712833.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies? Transl Gastroenterol Hepatol. 2026; 11:2. Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong J. PMID: 41675310; PMCID: PMC12887280.
      View in: PubMed   Mentions:
    17. Gastric neuroendocrine tumors associated with acid suppressant drugs are frequently associated with very prolonged drug use and may show unconventional morphologies. Hum Pathol. 2026 Feb; 168:106013. Azimpouran M, Waters KM, Hendifar AE, Gangi A, Kozak M, Guindi M, Lai KK, Larson BK, Hutchings DA. PMID: 41389897.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma. Front Immunol. 2025; 16:1568962. Chen PJ, Devkota S, Shiao S, Hendifar A, Yang JD. PMID: 41438742; PMCID: PMC12719415.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    19. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. N Engl J Med. 2025 Nov 20; 393(20):2012-2022. Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A, LITESPARK-015 Investigators. PMID: 41124218.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    20. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. JCO Precis Oncol. 2025 Aug; 9:e2400684. Ebia MI, Blais EM, Cui Y, Petricoin EF, Pishvaian M, Gaddam S, Gong J, Osipov A, Hendifar AE. PMID: 40834324; PMCID: PMC12379785.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer. 2025 Aug 15; 131(16):e70015. Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Márquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L. PMID: 40808295; PMCID: PMC12351156.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    22. Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma. Liver Cancer. 2026 May; 15(2):193-204. Choi GH, Kim HS, Luu M, Kuo A, Ayoub WS, Trivedi H, Wang Y, Vipani A, Chen PJ, Miles SA, Kaymen EA, Hendifar A, Todo T, Brennan TV, Voidonikolas G, Wisel SA, Steggerda J, Ferrone C, Kosari K, Nissen N, Parikh ND, Singal AG, Yang JD. PMID: 41063730; PMCID: PMC12503716.
      View in: PubMed   Mentions: 1  
    23. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. HPB (Oxford). 2025 Nov; 27(11):1379-1389. Ebia MI, Abbas AA, Levi A, Davelaar J, Rosenberg E, Atkins KM, Kamrava M, Lo S, Gaddam S, Gangi A, Kosari K, Arora A, Haladjian N, Laszlo M, Oppenheim S, Reckamp KL, Nissen N, Larson BK, Wachsman A, Gong J, Ferrone C, Hendifar AE, Osipov A. PMID: 40817027; PMCID: PMC12456971.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Oncologist. 2025 03 10; 30(3). Levi A, Blais E, Davelaar J, Ebia MI, Minasyan A, Nikravesh N, Gresham G, Zheng L, Chuy JW, Shroff RT, Wadlow RC, DeArbeloa P, Matrisian LM, Petricoin E, Pishvaian MJ, Gong J, Hendifar AE, Osipov A. PMID: 40079530; PMCID: PMC11904785.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nat Cancer. 2025 Feb; 6(2):253-258. Marabelle A, O'Malley DM, Hendifar AE, Ascierto PA, Motola-Kuba D, Penel N, Cassier PA, Bariani G, De Jesus-Acosta A, Doi T, Longo F, Miller WH, Oh DY, Gottfried M, Yao L, Jin F, Gozman A, Maio M. PMID: 39979665.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    26. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers (Basel). 2025 02 13; 17(4). Chang PJ, Hendifar AE, Gresham G, Ngo-Huang A, Oberstein PE, Parker N, Coveler AL, Precision Promise Consortium. PMID: 40002225; PMCID: PMC11853477.
      View in: PubMed   Mentions: 1  
    27. Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics Databases. Am J Gastroenterol. 2025 Apr 01; 120(4):890-904. Liang J, Rastegar R, El Helou M, Mathur K, Larson BK, Waters K, Vasireddy A, Randhawa N, Mubarak M, Advani R, Osipov A, Gong J, Hendifar A, Liu Q, Park KH, Watson R, Pandol SJ, Lo S, Gaddam S. PMID: 39225338; PMCID: PMC13134371.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Am J Clin Pathol. 2024 09 03; 162(3):314-326. Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF. PMID: 38642081; PMCID: PMC11369068.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. 5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms. Am J Clin Pathol. 2024 07 05; 162(1):41-50. Gonzalez-Mancera MS, Siref A, Kosari K, Nissen N, Gaddam S, Hendifar A, Osipov A, Waters K, Hutchings D, Guindi M, Larson BK. PMID: 38345293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Clin Transl Gastroenterol. 2024 Jul 01; 15(7):e00719. Wang J, Cui Y, Osipov A, Gong J, Pandol S, Lo S, Nissen N, Abbas A, Levi A, Hendifar A. PMID: 38822798; PMCID: PMC11272255.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Development and validation of a biomarker index for HCC treatment response. Hepatol Commun. 2024 07 01; 8(7). Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD. PMID: 38896084; PMCID: PMC11186807.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program. HPB (Oxford). 2024 08; 26(8):1082-1085. Hendifar A, Hitchins M, Lauzon M, Hatchell KE, Heald B, Pandol S, Naren AP, Osipov A. PMID: 38825435; PMCID: PMC11317177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas. J Neuroendocrinol. 2024 08; 36(8):e13399. Russo A, DiPeri T, Dumitra T, Tseng J, Pletcher E, Justo M, Chen C, Nissen N, Amersi F, Gong J, Hendifar A, Gangi A. PMID: 38760997.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Keratin 17 modulates the immune topography of pancreatic cancer. J Transl Med. 2024 05 10; 22(1):443. Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Bai JK, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer KR. PMID: 38730319; PMCID: PMC11087249.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    35. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. NPJ Precis Oncol. 2024 Feb 15; 8(1):36. Shishido SN, Lin E, Nissen N, Courcoubetis G, Suresh D, Mason J, Osipov A, Hendifar AE, Lewis M, Gaddam S, Pandol S, Kuhn P, Lo SK. PMID: 38360856; PMCID: PMC10869814.
      View in: PubMed   Mentions: 10  
    36. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity. Res Sq. 2023 Nov 30. Muranaka H, Billet S, Cruz-Hernández C, Ten Hoeve J, Gonzales G, Elmadbouh O, Zhang L, Smith B, Tighiouart M, You S, Edderkaoui M, Hendifar A, Pandol S, Gong J, Bhowmick N. PMID: 38076821; PMCID: PMC10705710.
      View in: PubMed   Mentions:
    37. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States. Gastro Hep Adv. 2024; 3(2):230-237. Kaur B, Yeo YH, Liang J, Luu M, Ayoub W, Kuo A, Trivedi H, Sankar K, Gong J, Hendifar A, Osipov A, Kosari K, Nissen N, Noureddin M, Singal AG, Yang JD. PMID: 39129956; PMCID: PMC11308067.
      View in: PubMed   Mentions: 2  
    38. TOPAZ-1: a new standard of care for advanced biliary tract cancers? Immunotherapy. 2023 05; 15(7):473-476. Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. PMID: 36950948.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma. Front Oncol. 2022; 12:1007134. Wang N, Gaddam S, Xie Y, Christodoulou AG, Wu C, Ma S, Fan Z, Wang L, Lo S, Hendifar AE, Pandol SJ, Li D. PMID: 36686811; PMCID: PMC9853434.
      View in: PubMed   Mentions: 5  
    40. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation. Pancreas. 2022 05 01; 51(5):463-468. Wang L, Zhou Z, Gaddam S, Wang N, Xie Y, Deng Z, Fan Z, Christodoulou AG, Han F, Lo SK, Wachsman AM, Hendifar AE, Jiang T, Pandol SJ, Li D. PMID: 35858211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World J Gastrointest Oncol. 2022 Feb 15; 14(2):511-524. Midthun L, Kim S, Hendifar A, Osipov A, Klempner SJ, Chao J, Cho M, Guan M, Placencio-Hickok VR, Gangi A, Burch M, Lin DC, Waters K, Atkins K, Kamrava M, Gong J. PMID: 35317320; PMCID: PMC8919005.
      View in: PubMed   Mentions: 2  
    42. Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report. AME Case Rep. 2021; 5:30. Lin CY, Mehta P, Waters KM, Chang E, Hendifar A, Osipov A, Burch M, Lin DC, Gangi A, Cho M, Gong J. PMID: 34312609; PMCID: PMC8256116.
      View in: PubMed   Mentions: 3  
    43. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 05; 32(5):600-608. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. PMID: 33539945.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    44. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci. 2020 Jul 23; 21(15). Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. PMID: 32718047; PMCID: PMC7432744.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    45. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2372-2382. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E, NETTER-1 study group. PMID: 32123969; PMCID: PMC7396396.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    46. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas. 2020 03; 49(3):393-407. Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. PMID: 32132518; PMCID: PMC7077976.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    47. Multiparametric Mapping Magnetic Resonance Imaging of Pancreatic Disease. Front Physiol. 2020; 11:8. Wang L, Gaddam S, Wang N, Xie Y, Deng Z, Zhou Z, Fan Z, Jiang T, Christodoulou AG, Han F, Lo SK, Wachsman AM, Hendifar AE, Pandol SJ, Li D. PMID: 32153416; PMCID: PMC7047169.
      View in: PubMed   Mentions: 20  
    48. Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. Pancreas. 2020 02; 49(2):e19-e20. Chorath J, Placencio-Hickok VR, Guan M, Nissen N, Kamrava M, Klempner SJ, Nassir Y, Hendifar A, Gong J. PMID: 32049953.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    49. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Magn Reson Med. 2020 08; 84(2):928-948. Wang N, Gaddam S, Wang L, Xie Y, Fan Z, Yang W, Tuli R, Lo S, Hendifar A, Pandol S, Christodoulou AG, Li D. PMID: 31961967; PMCID: PMC7323577.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    50. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan-Feb; 9(1):24-30. Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. PMID: 31670288; PMCID: PMC7038730.
      View in: PubMed   Mentions: 17  
    51. Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. JCO Oncol Pract. 2020 10; 16(10):701-702. Kim H, Jones AJ, Labadzhyan A, Placencio-Hickok VR, Wallace DJ, Gong J, Hendifar AE. PMID: 31790328.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Oncotarget. 2019 Oct 22; 10(58):6260-6268. Gong J, Blais EM, Bender JR, Guan M, Placencio-Hickok V, Petricoin EF, Pishvaian MJ, Gregory G, Tuli R, Hendifar AE. PMID: 31692857; PMCID: PMC6817448.
      View in: PubMed   Mentions: 3     Fields:    
    53. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2019 Dec; 2(4):505-515. Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF, Madhavan S. PMID: 32025647; PMCID: PMC6994017.
      View in: PubMed   Mentions: 50  
    54. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas. 2019 10; 48(9):1111-1118. Hendifar AE, Ramirez RA, Anthony LB, Liu E. PMID: 31609931; PMCID: PMC6830950.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    55. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clin Colorectal Cancer. 2019 12; 18(4):307-309. Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, Monjazeb AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M. PMID: 31563511.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    56. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol. 2019; 4:63. Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. PMID: 31559344; PMCID: PMC6737389.
      View in: PubMed   Mentions: 8  
    57. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. J Surg Oncol. 2019 Nov; 120(6):926-931. Manguso N, Nissen N, Hendifar A, Harit A, Mirocha J, Friedman M, Lipshutz HG, Amersi F. PMID: 31396982.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    58. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer. 2019 07; 121(3):264-270. Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. PMID: 31292535; PMCID: PMC6738081.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    59. 18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation. Adv Radiat Oncol. 2019 Oct-Dec; 4(4):613-622. David JM, Yue Y, Blas K, Hendifar A, Kabolizadeh P, Tuli R. PMID: 31681863; PMCID: PMC6817719.
      View in: PubMed   Mentions: 4  
    60. Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea. P T. 2019 Jul; 44(7):424-427. Cook R, Hendifar AE. PMID: 31258314; PMCID: PMC6590927.
      View in: PubMed   Mentions:
    61. Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. PLoS One. 2019; 14(6):e0218580. Baecker A, Kim S, Risch HA, Nuckols TK, Wu BU, Hendifar AE, Pandol SJ, Pisegna JR, Jeon CY. PMID: 31237889; PMCID: PMC6592596.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    62. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. Oncologist. 2019 12; 24(12):e1460-e1466. Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R, Shinde A. PMID: 31227648; PMCID: PMC6975959.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    63. Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterol. 2019; 6(1):e000299. Hitchins MP, Vogelaar IP, Brennan K, Haraldsdottir S, Zhou N, Martin B, Alvarez R, Yuan X, Kim S, Guindi M, Hendifar AE, Kalady MF, DeVecchio J, Church JM, de la Chapelle A, Hampel H, Pearlman R, Christensen M, Snyder C, Lanspa SJ, Haile RW, Lynch HT. PMID: 31275589; PMCID: PMC6577308.
      View in: PubMed   Mentions: 6     Fields:    
    64. Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. Hum Pathol. 2019 08; 90:37-44. Larson BK, Guan M, Placencio V, Tuli R, Hendifar AE. PMID: 31121193.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    65. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv Radiat Oncol. 2019 Jul-Sep; 4(3):513-519. Guan M, He I, Luu M, David J, Gong J, Placencio-Hickok VR, Reznik RS, Tuli R, Hendifar AE. PMID: 31360808; PMCID: PMC6639761.
      View in: PubMed   Mentions: 5  
    66. Pancreatic cancer 'mismatch' in Lynch syndrome. BMJ Open Gastroenterol. 2019; 6(1):e000274. Hendifar AE, Larson BK, Rojansky R, Guan M, Gong J, Placencio V, Tuli R, Hitchins M. PMID: 31275582; PMCID: PMC6577306.
      View in: PubMed   Mentions: 7     Fields:    
    67. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med. 2019 Mar 18; 8(1):9. Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. PMID: 30887236; PMCID: PMC6423251.
      View in: PubMed   Mentions: 56     Fields:    
    68. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06; 156(8):2242-2253.e4. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. PMID: 30836094.
      View in: PubMed   Mentions: 194     Fields:    Translation:Humans
    69. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019 Feb; 40:375-381. Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. PMID: 30635165; PMCID: PMC6412162.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    70. Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. Phys Imaging Radiat Oncol. 2019 Jan; 9:28-34. Lao Y, David J, Torosian A, Placencio V, Wang Y, Hendifar A, Yang W, Tuli R. PMID: 32190750; PMCID: PMC7079767.
      View in: PubMed   Mentions: 1  
    71. Pancreas Cancer-Associated Weight Loss. Oncologist. 2019 05; 24(5):691-701. Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L, Precision Promise Consortium. PMID: 30591550; PMCID: PMC6516128.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    72. Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. Am J Dermatopathol. 2018 Dec; 40(12):927-929. Siref A, Hendifar A, Balzer B. PMID: 29894357.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Adv Radiat Oncol. 2019 Apr-Jun; 4(2):302-313. David JM, Kim S, Placencio-Hickok VR, Torosian A, Hendifar A, Tuli R. PMID: 31011675; PMCID: PMC6460104.
      View in: PubMed   Mentions: 4  
    74. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018 Oct 08; 7(1):32. Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. PMID: 30294755; PMCID: PMC6174117.
      View in: PubMed   Mentions: 24     Fields:    
    75. Long-Term Outcomes after Elective versus Emergency Surgery for Small Bowel Neuroendocrine Tumors. Am Surg. 2018 Oct 01; 84(10):1570-1574. Manguso N, Gangi A, Nissen N, Harit A, Siegel E, Hendifar A, Amersi F. PMID: 30747671.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    76. Utility of Endoscopic Ultrasound-Guided Biopsy for Next-Generation Sequencing of Pancreatic Exocrine Malignancies. Pancreas. 2018 09; 47(8):990-995. Larson BK, Tuli R, Jamil LH, Lo SK, Deng N, Hendifar AE. PMID: 30028448.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    77. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy. Pancreas. 2018 09; 47(8):e55-e56. Hendifar AE, Delpassand ES, Kittleson MM, Tuli R. PMID: 30113434.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    78. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist. 2019 01; 24(1):54-61. Hendifar AE, Dhall D, Strosberg JR. PMID: 30104288; PMCID: PMC6324634.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS. PMID: 30105668; PMCID: PMC6510909.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    80. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. NPJ Digit Med. 2018; 1:27. Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL, Piantadosi S, Shinde AM. PMID: 31304309; PMCID: PMC6550281.
      View in: PubMed   Mentions: 93  
    81. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res. 2018 10 15; 24(20):5018-5027. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF. PMID: 29954777.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    82. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 09 01; 36(25):2578-2584. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, NETTER-1 Study Group. PMID: 29878866; PMCID: PMC6366953.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCTClinical Trials
    83. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018 06 04; 6(1):46. Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. PMID: 29866197; PMCID: PMC5987486.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansAnimals
    84. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol. 2018 10; 31(10):1523-1531. Marchevsky AM, Hendifar A, Walts AE. PMID: 29802361.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    85. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol. 2018; 2018. Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM. PMID: 30051098; PMCID: PMC6057747.
      View in: PubMed   Mentions: 112     Fields:    
    86. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018; 12:777-786. Gong J, Yan J, Forscher C, Hendifar A. PMID: 29670334; PMCID: PMC5896668.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    87. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest Oncol. 2018 Feb; 9(1):17-23. Hendifar AE, Chang JI, Huang BZ, Tuli R, Wu BU. PMID: 29564167; PMCID: PMC5848037.
      View in: PubMed   Mentions: 52  
    88. The Clinicopathological Aspects of Primary Presacral Neuroendocrine Neoplasms: One Center Experience. Pancreas. 2018 01; 47(1):122-129. Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE. PMID: 29215535.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    89. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. PMID: 29242283; PMCID: PMC6058330.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    90. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 02 01; 36(4):359-366. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. PMID: 29232172.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansCTClinical Trials
    91. Wearable activity monitors in oncology trials: Current use of an emerging technology. Contemp Clin Trials. 2018 01; 64:13-21. Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S. PMID: 29129704; PMCID: PMC12004692.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    92. Multifocality in Small Bowel Neuroendocrine Tumors. J Gastrointest Surg. 2018 02; 22(2):303-309. Gangi A, Siegel E, Barmparas G, Lo S, Jamil LH, Hendifar A, Nissen NN, Wolin EM, Amersi F. PMID: 29119527.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    93. Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. Clin Ther. 2017 Nov; 39(11):2135-2145. Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A. PMID: 29079389.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    94. Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. Am Surg. 2017 Oct 01; 83(10):1174-1178. Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F. PMID: 29391119.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    95. The role of pre-operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018 Feb; 117(2):207-212. Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A, Amersi F. PMID: 28940412.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    96. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Ann Surg Oncol. 2017 Nov; 24(12):3674-3682. Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. PMID: 28871564.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    97. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    98. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017 05; 15(5):555-562. Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. PMID: 28476735.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    99. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):516-522. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. PMID: 27978579; PMCID: PMC5665683.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansCTClinical Trials
    100. Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. Gastroenterology. 2017 04; 152(5):918-921.e2. Hendifar AE, Davies L, Tuli R. PMID: 28259790.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    101. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017 Feb; 8(1):127-138. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. PMID: 28280617; PMCID: PMC5334038.
      View in: PubMed   Mentions: 35  
    102. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, NETTER-1 Trial Investigators. PMID: 28076709; PMCID: PMC5895095.
      View in: PubMed   Mentions: 1536     Fields:    Translation:HumansCTClinical Trials
    103. Statins and pancreatic cancer. Oncol Lett. 2017 Mar; 13(3):1035-1040. Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM. PMID: 28454210; PMCID: PMC5403279.
      View in: PubMed   Mentions: 31  
    104. A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. Pancreas. 2017 01; 46(1):48-56. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X. PMID: 27984486.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    105. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol. 2017 03; 12(3):425-436. Hendifar AE, Marchevsky AM, Tuli R. PMID: 27890494.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    106. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 2017 Oct 13; 8(48):83446-83456. Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E, Brody JR. PMID: 29137355; PMCID: PMC5663527.
      View in: PubMed   Mentions: 35     Fields:    
    107. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol. 2016 Oct; 3(4):240-253. Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK. PMID: 29264192; PMCID: PMC5730836.
      View in: PubMed   Mentions: 25  
    108. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016; 6:99. Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. PMID: 27200288; PMCID: PMC4843105.
      View in: PubMed   Mentions: 28  
    109. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J Gastrointest Oncol. 2016 Apr; 7(2):239-47. Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. PMID: 27034792; PMCID: PMC4783734.
      View in: PubMed   Mentions: 5  
    110. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One. 2016; 11(3):e0152172. Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. PMID: 27015568; PMCID: PMC4807776.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    111. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol. 2016 Mar; 4(3):315-325. Gong J, Tuli R, Shinde A, Hendifar AE. PMID: 26998283; PMCID: PMC4774516.
      View in: PubMed   Mentions: 25  
    112. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
      View in: PubMed   Mentions: 157     Fields:    Translation:Humans
    113. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015 Apr; 6(2):185-200. Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. PMID: 25830038; PMCID: PMC4311092.
      View in: PubMed   Mentions: 47  
    114. Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Med Dosim. 2015; 40(1):47-52. Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R. PMID: 25445989.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    115. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014 Oct 10; 32(29):3299-306. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. PMID: 25185097; PMCID: PMC4588714.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    116. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014 Sep; 14(9):1051-61. Hendifar A, Tan CR, Annamalai A, Tuli R. PMID: 24898788.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    117. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014; 5:87. Reznik R, Hendifar AE, Tuli R. PMID: 24624093; PMCID: PMC3939680.
      View in: PubMed   Mentions: 14  
    118. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014; 5:88. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE. PMID: 24624094; PMCID: PMC3939686.
      View in: PubMed   Mentions: 64  
    119. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014 Apr; 50(6):1137-47. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. PMID: 24512981.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    120. A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed. World J Oncol. 2013 Oct; 4(4-5):217-220. Gong J, Delioukina ML, Hendifar AE. PMID: 29147360; PMCID: PMC5649932.
      View in: PubMed   Mentions:
    121. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 2013 Mar 16; 13:121. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM. PMID: 23497336; PMCID: PMC3605142.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    122. Moving beyond response criteria: new measures of success in the treatment of sarcomas. Curr Treat Options Oncol. 2012 Sep; 13(3):299-305. Hendifar AE, Ahlmann E, Allison DC, Hu J, Menendez L, Chawla SP. PMID: 22644834.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    123. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012; 2012:704872. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. PMID: 22550423; PMCID: PMC3329715.
      View in: PubMed   Mentions: 210  
    124. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. PMID: 22811834; PMCID: PMC3397601.
      View in: PubMed   Mentions: 118  
    125. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009 Oct 15; 15(20):6391-7. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. PMID: 19789331; PMCID: PMC2779768.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    126. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. PMID: 18987561.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    127. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008 Oct; 19(10):1734-41. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. PMID: 18550579; PMCID: PMC2735064.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    128. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    129. Myositis ossificans: a case report. Arthritis Rheum. 2005 Oct 15; 53(5):793-5. Hendifar AE, Johnson D, Arkfeld DG. PMID: 16208662.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Andrew's Networks
    Concepts (341)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (65)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-64-g4ee1c7b9 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California